Polyrizon Ltd., a biotech company specializing in intranasal hydrogels, has announced that it received a delisting notice from Nasdaq. The delisting is due to concerns over substantial shareholder dilution following the issuance of securities related to a purchase agreement dated March 31, 2025. Although the company's shares are not immediately affected, Polyrizon plans to request a hearing before a Nasdaq Hearings Panel to address the issue. This request will temporarily halt any suspension or delisting actions until the hearing and a subsequent decision by the Panel.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polyrizon Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9457098-en) on May 23, 2025, and is solely responsible for the information contained therein.